Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors (DCI), a proprietary class of anti-cancer medicines that employ cyclical drug delivery—alternating high concentrations with near-zero troughs—to deprive tumor cells of sustained growth signals while minimizing toxicity to healthy tissue. The company's lead program, a MEK inhibitor designed for MAPK pathway-driven solid tumors including pancreatic cancer and non-small cell lung cancer, targets a large patient population where conventional targeted therapies are limited by toxicity or adaptive resistance. Immuneering plans to commercialize its products directly in major markets while leveraging its enabling platform technologies—including proprietary bioinformatics for target discovery and humanized 3D tumor models—to advance its pipeline across validated cancer-signaling pathways.